Inspire Medical Systems, Inc. to Report Third Quarter 2020 Financial Results on November 2, 2020
Inspire Medical Systems, Inc. (NYSE: INSP) will release its third quarter 2020 financial results on November 2, 2020, post-market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Inspire Medical Systems, Inc. (NYSE: INSP) will release its third quarter 2020 financial results on November 2, 2020, post-market close. A conference call to discuss these results and recent business developments will begin at 5:00 PM Eastern Time. Inspire specializes in innovative solutions for obstructive sleep apnea, with its Inspire therapy being the first FDA-approved neurostimulation technology for moderate to severe cases. Details for joining the call and further information about the company are provided in the release.
Positive
- Inspire has developed the first FDA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea.
- Growth in the minimally invasive solutions market for patients with obstructive sleep apnea.
Negative
- None.
Details
News Market Reaction – INSP
The recorded move for INSP in the trading session of this news was -2.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the third quarter 2020 after the close of trading on Monday, November 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
| Monday, November 2rd @ 5:00 p.m. Eastern Time: | |
| Domestic: | 877-407-0792 |
| International: | 201-689-8263 |
| Conference ID: | 13710653 |
| Webcast: | http://public.viavid.com/index.php?id=141564 |
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.